Market Overview

Bristol-Myer Opdivo Demonstrates Superior Survival Compared to Ocetaxel for Previously-Treated Squamous NSCLC in Phase 3 Trial

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News Press Releases

 

Related Articles (BMY)